DETECTION METHOLOGY FOR MYCOBACTERIA TUBERCULOSIS
DETECTION METHOLOGY FOR MYCOBACTERIA TUBERCULOSIS
批准号:
2536423
负责人:
Mary Haak-Frendscho
金额:
$9.08万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-04-01 至 1999-05-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Early, definition detection of pathogenic agents often is key to
effective treatment and full recovery. Although DNA and protein-based
detection systems are widely used to detect pathogen and disease
markers, a number of systems have limited capacity to rapidly produce
reagents specific for existing and emerging new pathogens.
The overall goal of the proposed research is to develop a general, non-
immunological method to rapidly obtain reagents with high affinity and
specificity for detecting protein targets specific for Mycobacteria
tuberculosis. The approach is based on a recombinant display library
that uses biotin carboxylase carrier protein (BCCP) as a scaffold. In
Phase I, methods will be developed to assay and combine individual
isolates obtained from this library to create bispecific detection
complexes. The secreted protein antigens Ag85, 38kDa and 45/47kDa
complex of Mycobacteria tuberculosis, the causative agent of
tuberculosis, will serve as the initial targets.
Phase II studies will apply the technology to obtain bispecific reagents
for other targets if necessary, incorporate the bispecifics into
existing assay formats and test assay effectiveness in clinical samples.
Phase III will involve final process development, incorporation into
automated diagnostic systems, and application in commercial markets via
partnerships with private pharmaceutical diagnostics firms.
PROPOSED COMMERCIAL APPLICATION
Anticipated commercial applications include new confirmatory diagnostic
systems with greatly improved specificity and instrument compatibility,
new detection reagents for research and clinical applications, and new
manufacturing processes for licensing. Research product applications
will be commercialized through Promega's own network; clinical product
applications will be commercialized through a pharmaceutical partner.
Commercially, Mycobacteria tuberculosis is an excellent target since it
is currently on the rise, with much of the increase linked to the AIDS
epidemic.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
In vivo delivery of Ab-directed CRISPR ribonucleoproteins for anal cancer immunotherapy
-
批准号:10821884
-
项目类别:
-
资助金额:$104.38万
-
财政年份:2023
-
负责人:Mary Haak-Frendscho
-
依托单位:
海外基金